Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC

NCT05369000 is registered in ClinicalTrials.gov with Lava Therapeutics as lead sponsor.

NCT NCT05369000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05369000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC
Lead sponsor
Lava Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
January 17, 2022
Completion date
June 18, 2025
Enrollment
96 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer